In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors.

被引：0
|
作者：
Arris, CE
Boyle, FT
Calvert, AH
Curtin, NJ
Dewsbury, PJ
Endicott, JA
Gibson, AE
Golding, BT
Grant, S
Griffin, RJ
Johnson, LN
Noble, MEM
Newell, DR
Sausville, E
Schultz, R
机构：
[1] Univ Newcastle Upon Tyne, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Univ Oxford, Oxford OX1 3QU, England
[3] NCI, DTP, Washington, DC USA
[4] Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England
来源：
BRITISH JOURNAL OF CANCER | 1999年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
110
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors
    Lee, Jinho
    Kim, Kyoung-Hee
    Jeong, Shinwu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (14) : 4203 - 4205
  • [2] Discovery and evaluation of dual CDK1 and CDK2 inhibitors
    Payton, M
    Chung, G
    Yakowec, P
    Wong, A
    Powers, D
    Xiong, L
    Zhang, N
    Leal, J
    Bush, TL
    Santora, V
    Askew, B
    Tasker, A
    Radinsky, R
    Kendall, R
    Coats, S
    CANCER RESEARCH, 2006, 66 (08) : 4299 - 4308
  • [3] Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors.
    Bentley, J
    Arris, CE
    Boyle, FT
    Calvert, AH
    Curtin, NJ
    Endicott, JA
    Gibson, AE
    Golding, BT
    Grant, S
    Griffin, RJ
    Jewsbury, PJ
    Johnson, LN
    Noble, MEM
    Newell, DR
    CLINICAL CANCER RESEARCH, 2000, 6 : 4532S - 4532S
  • [4] Cdk1: the dominant sibling of Cdk2
    Tarig Bashir
    Michele Pagano
    Nature Cell Biology, 2005, 7 : 779 - 781
  • [5] Cdk1: the dominant sibling of Cdk2
    Bashir, T
    Pagano, M
    NATURE CELL BIOLOGY, 2005, 7 (08) : 779 - 781
  • [6] Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1
    Sakurikar, Nandini
    Eastman, Alan
    CELL CYCLE, 2016, 15 (09) : 1184 - 1188
  • [7] Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer
    Kim, S. J.
    Nakayama, S.
    Miyoshi, Y.
    Taguchi, T.
    Tamaki, Y.
    Matsushima, T.
    Torikoshi, Y.
    Tanaka, S.
    Yoshida, T.
    Ishihara, H.
    Noguchi, S.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 68 - 72
  • [8] Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases
    Mayi, Therese
    Facca, Celine
    Anne, Sandrine
    Vernis, Laurence
    Huang, Meng-Er
    Legraverend, Michel
    Faye, Gerard
    JOURNAL OF BIOTECHNOLOGY, 2015, 195 : 30 - 36
  • [9] Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases
    Mayi, T.
    Huang, M. E.
    Vernis, L.
    Legraverend, M.
    Faye, G.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S80 - S80
  • [10] CDK1 AND CDK2 ACTIVITY IS A STRONG PREDICTOR OF RENAL CELL CANCER RECURRENCE
    Hongo, F.
    Takaha, N.
    Kimura, Y.
    Nakamura, T.
    Mikami, K.
    Nakayama, S.
    Matsushima, T.
    Ishihara, H.
    Sakai, T.
    Miki, T.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 138 - 139
12345